Drug Profile
Research programme: growth hormone-related compounds - Neuren
Alternative Names: NNZ-3006Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Neuren Pharmaceuticals
- Class Growth hormones
- Mechanism of Action Insulin-like growth factor I inhibitors; Somatotropin receptor agonists; Somatotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Metabolic disorders; Obesity; Somatotropin deficiency
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in New Zealand
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in New Zealand
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in New Zealand